
Dr. Daniel Drucker’s research helped pave the way for Ozempic, the blockbuster GLP-1 class drug. The endocrinologist has been researching the effects on Ozempic’s active ingredient semaglutide in the body for decades.Today he’ll show us around his lab and explain how a stout lizard kept in a freezer helped unlock the science behind a drug taken by more than a million Canadians.
Then, health reporter Kelly Grant tells us about rising obesity rates in Canada, and we’ll hear from a doctor who prescribes GLP-1s— and a patient who takes them.
This is part of a three-part series. The next episode is next Monday, March 2nd.
You can contact the National Eating Disorders Information Centre at their toll-free hotline at 1-866-NEDIC-20 or visit their website.
Questions? Comments? Ideas? Email us at [email protected]
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Mais episódios de "The Decibel"



Não percas um episódio de “The Decibel” e subscrevê-lo na aplicação GetPodcast.








